Kalaris posted an increased net loss in Q2 2025 driven by R&D and G&A expenses related to its Phase 1 trial of TH103, while maintaining strong cash reserves post-merger with AlloVir.

AlloVir, a biopharmaceutical company, reported a net loss of $58.8 million for the year ended December 31, 2024, a significant improvement from the $190.4 million loss in the previous year. This reduction in losses was primarily driven by the discontinuation of three Phase 3 registrational trials and a comprehensive review of strategic alternatives, leading to a substantial decrease in research and development expenses. The company is currently focused on a proposed merger with Kalaris Therapeutics, Inc., which is expected to close in the first quarter of 2025.

AlloVir reported a net loss of $44.3 million, or $0.39 per share, for the third quarter ended September 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $213.3 million as of September 30, 2023, providing runway through all pivotal trial data readouts.

AlloVir reported its Q2 2023 financial results, highlighting the progress of its allogeneic, off-the-shelf virus-specific T cell (VST) programs, including posoleucel. The company's three Phase 3 global registrational trials for posoleucel are ongoing, with data expected in the second half of 2024. AlloVir's cash position is expected to fund operations into 2025, through anticipated data readouts from the posoleucel Phase 3 trials.

AlloVir reported a net loss of $41.2 million, or $0.44 per share, for the first quarter of 2023. The company's research and development expenses were $30.7 million, while general and administrative expenses were $12.5 million. As of March 31, 2023, AlloVir had cash, cash equivalents, and short-term investments of $202.6 million.

AlloVir reported its full-year 2022 financial results, highlighting the progress of its allogeneic, off-the-shelf, virus-specific T cell (VST) programs and providing an outlook for 2023 and into 2024. The company's cash position remains strong, with $233.8 million as of year-end 2022.

AlloVir reported a net loss of $42.1 million, or $0.50 per share, for the third quarter ended September 30, 2022. The company's research and development expenses were $30.0 million, and general and administrative expenses were $12.9 million. As of September 30, 2022, AlloVir had cash, cash equivalents, and marketable securities of $264.1 million.

AlloVir reported a net loss of $44.6 million, or $0.69 per share, for the quarter ended June 30, 2022. The company's cash, cash equivalents, and marketable securities totaled $172.7 million as of June 30, 2022, which, combined with proceeds from a registered direct offering, are expected to fund Phase 3 trials of posoleucel and global regulatory submissions.

AlloVir reported a net loss of $43.9 million, or $0.69 per share, for the first quarter ended March 31, 2022. The company's research and development expenses were $29.1 million, and general and administrative expenses were $14.1 million. As of March 31, 2022, AlloVir had cash, cash equivalents, and marketable securities of $201.4 million.

AlloVir reported its full-year 2021 financial results, highlighting advancements in its clinical development programs, including three Phase 3 registrational studies for posoleucel. The company also reported a strong cash position with $248.1 million at year-end.

AlloVir reported a net loss of $45.5 million, or $0.72 per share, for the third quarter ended September 30, 2021. The company's research and development expenses were $33.1 million, and general and administrative expenses were $12.4 million. As of September 30, 2021, AlloVir had cash, cash equivalents, and marketable securities of $275.8 million.

AlloVir reported financial results for Q2 2021. The net loss was $37.6 million, or $0.60 per share. As of June 30, 2021, AlloVir had cash, cash equivalents, and marketable securities of $313.3 million.

AlloVir reported a net loss of $30.9 million for the first quarter of 2021, with increased research and development and general and administrative expenses compared to the same period in 2020. The company's cash, cash equivalents, and marketable securities totaled $337.0 million as of March 31, 2021.

AlloVir reported its full-year 2020 financial results, highlighting the initiation of multiple clinical trials and FDA clearance for ALVR106. The company's cash, cash equivalents, and marketable securities totaled $356.3 million as of December 31, 2020.

AlloVir completed its initial public offering, raising $317.7 million in gross proceeds, and is focused on executing its pipeline objectives, including commencing pivotal and proof-of-concept studies across three cell therapies.

AlloVir reported a net loss of $11.6 million, or $4.43 per share, for the quarter ended June 30, 2020. The company's cash, cash equivalents, and marketable securities totaled $104.5 million as of June 30, 2020. They closed an initial public offering raising $317.7mm in gross proceeds in August.